Goals of Treatment and Special Considerations in Hypoparathyroidism

Dr. Ferenczi outlines six standardized treatment goals based on the 2016 consensus guidelines, the 2022 international task force, and 2025 best practices: (1) preventing signs and symptoms of hypocalcemia; (2) maintaining serum calcium at or slightly below the low end of the normal range; (3) keeping the calcium-phosphate product below 55; (4) avoiding hypercalciuria; (5) avoiding hypercalcemia; and (6) preventing renal and extraskeletal calcification. She emphasizes that the therapeutic target is the lowest serum calcium compatible with being symptom-free—not normal calcemia—because without PTH the kidneys cannot reabsorb filtered calcium efficiently, and pushing calcium into the mid-to-high normal range floods the urine with calcium, accelerating renal complications.

Conventional therapy consists of active vitamin D (calcitriol or alfacalcidol) plus calcium supplementation, with correction of magnesium and 25-hydroxyvitamin D status. PTH replacement is reserved for cases where conventional therapy fails to achieve adequate biochemical control or acceptable quality of life. Thiazide diuretics are used adjunctively to reduce hypercalciuria.

ADH1, caused by a gain-of-function mutation in the calcium-sensing receptor (CaSR), requires a fundamentally different approach. The overactive CaSR on both parathyroid cells and distal renal tubular cells produces more severe hypercalciuria through two concurrent mechanisms, making aggressive calcium normalization especially dangerous—risking nephrocalcinosis, kidney stones, CKD, and intracerebral calcification. Dr. Ferenczi advises much lower calcium targets (approximately 7.2–8.4 mg/dL), twice-daily active vitamin D titrated to symptom control rather than biochemical normalization, and sparing use of calcium supplementation. She flags the calcilytic agent encaleret—now in the Calgary phase 3 trial—as a targeted therapeutic approach for ADH1 that resets the overactive CaSR set point.

In the next episode, "Overview of the Hypoparathyroidism Treatment Landscape," Dr. Khosravi provides a comprehensive overview of the treatment landscape for hypoparathyroidism, from first-line calcium and active vitamin D therapy to the newly FDA-approved PTH replacement agent palopegteriparatide.